Since ALCL was first described as a clinical entity by Stein et al. (1985) [20], this lesion was classified as Ki-1+ ALCL and currently as Ki-1 (CD30) [17], which corresponds to a cohesive proliferation of large pleomorphic cells that express CD30. The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.